Physician Education: Bridging Clinical Research and Patient Care

Antiretroviral Therapy in HIV Infection: Updated Guidelines on When to Start, What to Use, and How to Monitor

Tuesday, July 28, 2015

1:00 PM (ET), 12:00 PM (CT), 11:00 AM (MT), 10:00 AM (PT)

Overview

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV disease. This webinar will utilize a case-based approach to review recent developments in antiretroviral therapy, including updated treatment guidelines, new antiretroviral co-formulations, and the START trial. The goal is to educate HIV providers on new data regarding when to start ART, what to use for initial therapy, and how to monitor the response to therapy.

Learning Objectives

On completion of this IAS–USA live activity, participants will be able to:

  • Describe recently updated antiretroviral treatment guidelines
  • Describe the implications of the recently reported START trial
  • Identify patient-specific factors in choosing an initial antiretroviral regimen
  • Apply new guidelines on laboratory monitoring of response to therapy

Registration

Who Should Attend

This webinar is designed for physicians who are actively treating or will be treating patients with HIV infection.

This activity is also relevant for other practitioners including nurse practitioners and other nursing professionals, physician assistants, pharmacists, and others.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Monday, July 27, 2015, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

Education Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-15-172-L01-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

PLATINUM SUPPORTERS
Gilead Sciences, Inc
ViiV Healthcare

GOLD SUPPORTERS
Bristol-Myers Squibb
Janssen Therapeutics
Merck & Co, Inc

Additional support for select activity types in this national program is provided by:
AbbVie

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.

Presenter(s)

Webinar Link

You may view or share the archived recording for educational purposes, however, it is not available for CME credit.